衰變加速因子(CD55)活性蛋白
Active Cluster Of Differentiation 55 (CD55)
DAF; CR; TC; Complement decay-accelerating factor; Decay Accelerating Factor
- 編號APA468Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)5.9
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 暫無報(bào)價(jià) 暫無報(bào)價(jià) 暫無報(bào)價(jià) 暫無報(bào)價(jià) 暫無報(bào)價(jià)
- 欲了解實(shí)際交易價(jià)格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
Cluster Of Differentiation 55 (CD55), also known as Decay Accelerating Factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that belongs to the RCA (regulators of complement activation) family and is expressed on all cells that are bathed in plasma, such as blood cells and endothelial cells. CD55 functions as a complement regulator, accelerating the decay of C3 and C5 convertases, thereby inhibiting the formation of the membrane attack complex (MAC) and preventing complement-mediated cell lysis. It plays a crucial role in protecting host cells from complement damage and is involved in various physiological and pathological processes, including immune complex clearance and inflammation.When CD55 binds to C4a, CD55 can regulate the activity of the complement system and prevent cell damage caused by over-activation of the complement.. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human CD55 and recombinant human C4a. Briefly,CD55 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to C4a-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-CD55 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human CD55 and recombinant human C4a was shown in Figure 1, the EC50?for this effect is0.18ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA468Hu01 | 衰變加速因子(CD55)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA468Hu61 | 衰變加速因子(CD55)活性蛋白 | Cell?culture;?Activity?Assays. |
APA468Hu01 | 衰變加速因子(CD55)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA468Hu61 | 衰變加速因子(CD55)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA468Hu01 | 衰變加速因子(CD55)多克隆抗體 | WB; ICC; IHC-P; IHC-F; ELISA. |
MAA468Hu25 | 衰變加速因子(CD55)單克隆抗體 | WB; IHC; ICC; IP. |
MAA468Hu24 | 衰變加速因子(CD55)單克隆抗體 | WB; IHC; ICC; IP. |
MAA468Hu21 | 衰變加速因子(CD55)單克隆抗體 | WB; IHC; ICC; IP. |
MAA468Hu23 | 衰變加速因子(CD55)單克隆抗體 | WB |
MAA468Hu22 | 衰變加速因子(CD55)單克隆抗體 | WB; IHC; ICC; IP. |
MAA468Hu26 | 衰變加速因子(CD55)單克隆抗體 | WB; IHC; ICC; IP. |
RAA468Hu21 | 衰變加速因子(CD55)重組抗體 | WB; IFC; IHC; IP; FCM |
FAA468Hu02 | 抗衰變加速因子(CD55)單克隆抗體 | Flow cytometry. |
FAA468Hu04 | 抗衰變加速因子(CD55)單克隆抗體 | Flow cytometry. |
FAA468Hu86 | 抗衰變加速因子(CD55)單克隆抗體(異硫氰酸熒光素標(biāo)記) | FCM |
SEA468Hu | 衰變加速因子(CD55)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA468Hu | 衰變加速因子(CD55)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA468Hu01 | 衰變加速因子(CD55)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It(ELISA Kit) Yourself" |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Biomarkers. | Role of IL-1ra and Granzyme B as biomarkers in active Crohn's disease patients [pubmed:28972805] |
Medicine (Baltimore) | Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions [34397724] |